Gradalis

Gradalis is a late-stage biotechnology company focused on the development and commercialization of novel personalized therapies for the treatment of cancer. Vigil, our proprietary immunotherapy platform for multiple advanced cancer indications, is under development, with the lead program targeting patients with Ewing's sarcoma.